Klaria Pharma Holding AB (OSTO:KLAR) ROCE % : -30.96% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Klaria Pharma Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Klaria Pharma Holding AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -30.96%.

Klaria Pharma Holding AB ROCE % Historical Data

The historical data trend for Klaria Pharma Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klaria Pharma Holding AB ROCE % Chart

Klaria Pharma Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-23.90

-50.96

-56.27

-76.03

-25.17

Klaria Pharma Holding AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-23.67	-58.05	-69.24	76.02	-30.96

Klaria Pharma Holding AB ROCE % Calculation

Klaria Pharma Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-14.795	/	( ( (120.271 - 43.848)	+	(72.948 - 31.814) )	/ 2 )
	=	-14.795	/	( (76.423	+	41.134)	/ 2 )
	=	-14.795	/	58.7785
	=	-25.17 %

Klaria Pharma Holding AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-11.216	/	( ( (72.948 - 31.814)	+	(69.012 - 37.682) )	/ 2 )
	=	-11.216	/	( ( 41.134	+	31.33 )	/ 2 )
	=	-11.216	/	36.232
	=	-30.96 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Klaria Pharma Holding AB (OSTO:KLAR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Klaria Pharma Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Klaria Pharma Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Klaria Pharma Holding AB (OSTO:KLAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Klaria Pharma Holding AB (OSTO:KLAR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

6FN:Germany

Address

Virdings Alle 2, Uppsala, SWE, 754 50

Website

https://www.klaria.com

Klaria Pharma Holding AB is engaged in the development and commercialization of pharmaceutical products in Sweden for migraine and cancer-related pain. Its operations are based on a patented drug delivery platform in the form of an alginate-based polymer film. Majority of the group's operations are conducted in Sweden.

Klaria Pharma Holding AB (OSTO:KLAR) Headlines

No Headlines